Post Test and Evaluation

Please note that to receive credit you must achieve a score of at least 70%.

Physicians: Certificate of Credit will be emailed within 4 weeks of successful completion of the activity.

Pharmacists: The information that you participated will be uploaded to CPE Monitor within 4 weeks of successful completion of the activity and you will be able to access your credits from the profile you set up with NABP. For more information, please visit http://www.nabp.net/.

Question Title

1. Which of the following statements regarding MRSA infections in the US is least accurate?

Hospital-onset MRSA infection rates are decreasing.

Community-associated MRSA infection rates are decreasing.

MRSA is a leading cause of skin and soft tissue infections.

MRSA is a leading cause of catheter-related infections.

Question Title

2. Rapid diagnostic tests to identify MRSA infections include all of the following except:

PNA FISH

PCR

MALDI TOF

beta-D-glucan

Question Title

3. The leading cause of blood infections in hospitals is:

Streptococcus pneumoniae

Enterococcus faecium

Escherichia coli

Klebsiella pneumoniae

Question Title

4. First-line therapy for the treatment of infection caused by an ESBL-producing Enterobacteriaceae is:

Fluoroquinolone

Third-generation cephalosporin

Carbapenem

Colistin

Question Title

5. Which of the following carbapenemases is a metallo-beta-lactamase?

NDM

KPC

OXA-48

SME

Question Title

6. Which of the following patient characteristics is more likely associated with infections caused by non-resistant P. aeruginosa than MDR P. aeruginosa?

Mechanical ventilation

Prior admission to ICU

Prior use of antipseudomonal antimicrobial

Prior use of non-antipseudomonal antimicrobial

Question Title

7. After a first C. difficile infection (CDI) episode, the rate of a recurrent episode is:

10%

20%

40%

75%

Question Title

8. First-line therapy for an initial episode of severe CDI is:

Metronidazole

Vancomycin

Probiotics

Fecal transplant

Question Title

9. Which of the following characteristics is an IDSA/SHEA criterion for severe CDI?

WBC >15,000/mm3

WBC >30,000/mm3

SCr <1.5 × baseline

Recent prior use of an antimicrobial

Question Title

10. Compared to vancomycin, the use of fidaxomicin in the treatment of CDI resulted in significantly:

Higher overall clinical cure rates

Higher clinical cure rates for moderate-to-severe CDI only

Higher clinical cure rates in cancer patients

Lower rates of overall recurrent infection